AbbVie Q2 FY2026: revenue up 10.2%, adjusted EPS $3.65
Revenue grew 10.2% and GAAP gross margin jumped to 74.7%, but adjusted EPS of $3.65 came in just under the $3.6761 consensus, and full-year guidance was trimmed by $0.04 at the midpoint. Read this quarter in two layers: the operating business in immunology and neuroscience is compounding, while the GAAP-to-adjusted gap and the pending $10.9 billion Apogee acquisition explain most of the noise.
1 · Expected vs. Actual
Free preview belowGAAP EPS of $2.03 rose 290.4% from $0.52, but adjusted EPS of $3.65 is the number management guides on. That was $0.0261 below the $3.6761 consensus, a shortfall of about 0.7%. The gap between GAAP and adjusted is $1.62 per share, driven by $1.689 billion of intangible asset amortization and a $1.518 billion fair-value swing in contingent consideration.
Revenue of $16.99 billion rose 10.2% on a reported basis and 9.5% in constant currency, with immunology up 15.1% and neuroscience up 20.3%. Oncology fell 1.5% and aesthetics rose just 0.3%. One caveat: the five segment lines add up to $15.881 billion, about $1.109 billion less than reported revenue, so treat the segment mix as directional rather than exhaustive.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.